iRadimed (IRMD)
(Delayed Data from NSDQ)
$66.17 USD
+7.83 (13.42%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $66.17 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IRMD 66.17 +7.83(13.42%)
Will IRMD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IRMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IRMD
iRadimed (IRMD) Q2 Earnings and Revenues Surpass Estimates
Integer (ITGR) Q2 Earnings Lag Estimates
IRMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for June 12th
IRadimed (IRMD) Lags Q1 Earnings Estimates
Integer (ITGR) Beats Q1 Earnings and Revenue Estimates
Other News for IRMD
Iradimed outlines $100M revenue run-rate for 2026 driven by new 3870 pump launch
IRADIMED CORPORATION (IRMD) Q2 2025 Earnings Call Transcript
IRMD Projects FY25 Revenue Growth to Reach Up to $82.5 Million
IRMD Anticipates Solid Q3 Revenue Growth
Iradimed (IRMD) Achieves Record Q2 Revenue with Strong Growth Prospects